{"id":31849,"date":"2020-04-27T16:04:54","date_gmt":"2020-04-27T10:34:54","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=31849"},"modified":"2020-04-27T16:04:54","modified_gmt":"2020-04-27T10:34:54","slug":"hypertension-induced-by-tyrosine-kinase-inhibitor","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/","title":{"rendered":"Hypertension induced by tyrosine kinase inhibitor"},"content":{"rendered":"<h2><span style=\"color: #008000;\">Hypertension induced by tyrosine kinase inhibitor<\/span><\/h2>\n<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/oTiCZ3nuqZo\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen=\"\"><\/iframe><\/p>\n<p>Well known adverse effects of chemotherapeutic agents are <a href=\"https:\/\/johnsonfrancis.org\/professional\/anthracycline-cardiotoxicity-2-3\/\">cardiomyopathy<\/a> and myocarditis leading to heart failure and arrhythmias. Hypertension induced by tyrosine kinase inhibitor (TKI) is an important adverse effect and has specific mechanisms. Hypertension is noted with vascular endothelial growth factor (VEGF) and vascular signalling pathway (VSP) inhibitors [1].<\/p>\n<p>The incidence ranges from 5% to 80% among VEGF inhibitors and is dose dependent. Incidence of hypertension is lower in new generation small molecule TKI [1]. Mechanism of hypertension is through vascular signally pathway inhibition which causes decrease in nitric oxide (vasodilator) and increased endothelin (vasoconstrictor) production. Resulting vasoconstriction leads to hypertension. Angiotensin system inhibitors and calcium channel blockers are used in the treatment of the hypertension induced by vascular signalling pathway inhibitors. The newer vascular signalling pathway inhibitors are cediranib, axitinib, pazopanib, and ponatinib [1].<\/p>\n<p>A higher baseline systolic blood pressure has been shown to be a predictor of tyrosine kinase inhibitor induced hypertension in patients with renal cancer [2]. They used angiotensin receptor blockers and calcium channel blockers as first line agents and found no difference between the two. The VEGF-TKI sorafenib, sunitinib and axitinib were studied in this report. As proteinuria is associated with VEGF-TKI, use of angiotensin receptor blockers which can reduce proteinuria may be beneficial.<\/p>\n<p><strong><span style=\"color: #0000ff;\">References<\/span><\/strong><\/p>\n<ol>\n<li>Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29931399\">Curr Oncol Rep. 2018 Jun 21;20(8):65.<\/a><\/li>\n<li>Izumi K, Itai S, Takahashi Y, Maolake A, Namiki M. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4063571\/\">Oncol Lett. 2014 Jul;8(1):305-308.&nbsp;<\/a><\/li>\n<\/ol>\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hypertension induced by tyrosine kinase inhibitor Well known adverse effects of chemotherapeutic agents are cardiomyopathy and myocarditis leading to heart failure and arrhythmias. Hypertension induced by tyrosine kinase inhibitor (TKI) is an important adverse effect and has specific mechanisms. Hypertension is noted with vascular endothelial growth factor (VEGF) and vascular signalling pathway (VSP) inhibitors [1]. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":31860,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[23],"tags":[],"class_list":["post-31849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardio-oncology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"description\" content=\"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors &amp; vascular signalling pathway inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors &amp; vascular signalling pathway inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-27T10:34:54+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Hypertension induced by tyrosine kinase inhibitor\",\"datePublished\":\"2020-04-27T10:34:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/\"},\"wordCount\":245,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"Cardio Oncology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/\",\"name\":\"Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2020-04-27T10:34:54+00:00\",\"description\":\"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors & vascular signalling pathway inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/hypertension-induced-by-tyrosine-kinase-inhibitor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hypertension induced by tyrosine kinase inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders","description":"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors & vascular signalling pathway inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/","og_locale":"en_US","og_type":"article","og_title":"Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders","og_description":"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors & vascular signalling pathway inhibitors.","og_url":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2020-04-27T10:34:54+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Hypertension induced by tyrosine kinase inhibitor","datePublished":"2020-04-27T10:34:54+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/"},"wordCount":245,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#primaryimage"},"thumbnailUrl":"","articleSection":["Cardio Oncology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/","url":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/","name":"Hypertension induced by tyrosine kinase inhibitor - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#primaryimage"},"thumbnailUrl":"","datePublished":"2020-04-27T10:34:54+00:00","description":"Hypertension induced by tyrosine kinase inhibitor: seen mainly with vascular endothelial growth factor inhibitors & vascular signalling pathway inhibitors.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/hypertension-induced-by-tyrosine-kinase-inhibitor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Hypertension induced by tyrosine kinase inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/31849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=31849"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/31849\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=31849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=31849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=31849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}